The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | CD19-directed CAR-T in patients with R/R high-grade lymphoma
Claire Roddie, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, gives an overview of the findings of a study which investigated the outcomes of patients with relapsed/refractory (R/R) high-grade lymphoma, deemed unfit for autologous stem cell transplantation (ASCT), who receive CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study analyzed data from 400 patients with R/R high-grade lymphoma who were approved for treatment with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) between December 2018 and November 2020 across 10 UK centers. Dr Roddie reports that 20% of patients approved for CAR-T therapy were deemed unfit for ASCT, of which 65% underwent infusion. Dr Roddie discusses the study’s finding and comments on implications for clinical practice and patient selection for CAR-T therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
